Quality-Adjusted Survival Analysis of Neurologic Events with Cilta-Cel Versus Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population